{"id":206175,"date":"2023-01-10T12:20:27","date_gmt":"2023-01-10T04:20:27","guid":{"rendered":"http:\/\/www.namnewsnetwork.org\/?p=206175"},"modified":"2023-01-10T12:20:27","modified_gmt":"2023-01-10T04:20:27","slug":"adagene-announces-interim-data-demonstrating-safety-and-confirmed-clinical-responses-of-anti-ctla-4-safebody-adg126-up-to-10-mg-kg-with-repeat-cycles-in-combination-with-anti-pd-1-therapy-from-d","status":"publish","type":"post","link":"http:\/\/namnewsnetwork.org\/?p=206175","title":{"rendered":"Adagene Announces Interim Data Demonstrating Safety And Confirmed Clinical Responses Of Anti-CTLA-4 SAFEbody\u00ae ADG126 Up To 10 mg\/kg with Repeat Cycles in Combination with Anti-PD-1 Therapy from Dose Escalation Portion of Phase 1b\/2 Trial"},"content":{"rendered":"\n<p><strong>SAN DIEGO and SUZHOU, China, Jan 10 (Bernama-GLOBE NEWSWIRE) &#8212;<\/strong>&nbsp;Adagene Inc. (\u201cAdagene\u201d) (Nasdaq: ADAG), a biotechnology company committed to transforming the discovery and development of novel antibody-based immunotherapies, today announced data for its masked anti-CTLA-4 SAFEbody, ADG126, in combination with anti-PD-1 therapy in patients with advanced\/metastatic solid tumors.<\/p>\n\n\n\n<p>The results (as of January 6, 2023) in 14 heavily pre-treated patients demonstrate the safety and initial efficacy profiles of ADG126 in combination with anti-PD-1 treatment. Adagene plans to present the detailed dose escalation data at an upcoming medical conference in the first half of 2023.<\/p>\n\n\n\n<p><a href=\"http:\/\/mrem.bernama.com\/viewsm.php?idm=45178\">http:\/\/mrem.bernama.com\/viewsm.php?idm=45178<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>SAN DIEGO and SUZHOU, China, Jan 10 (Bernama-GLOBE NEWSWIRE) &#8212;&nbsp;Adagene Inc. (\u201cAdagene\u201d) (Nasdaq: ADAG), a biotechnology company committed to transforming the discovery and development of novel antibody-based immunotherapies, today announced data for its masked anti-CTLA-4 SAFEbody, ADG126, in combination with anti-PD-1 therapy in patients with advanced\/metastatic solid tumors. The results (as of January 6, 2023) [&hellip;]<\/p>\n","protected":false},"author":14,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":[],"categories":[315],"tags":[],"_links":{"self":[{"href":"http:\/\/namnewsnetwork.org\/index.php?rest_route=\/wp\/v2\/posts\/206175"}],"collection":[{"href":"http:\/\/namnewsnetwork.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"http:\/\/namnewsnetwork.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"http:\/\/namnewsnetwork.org\/index.php?rest_route=\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"http:\/\/namnewsnetwork.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=206175"}],"version-history":[{"count":1,"href":"http:\/\/namnewsnetwork.org\/index.php?rest_route=\/wp\/v2\/posts\/206175\/revisions"}],"predecessor-version":[{"id":206176,"href":"http:\/\/namnewsnetwork.org\/index.php?rest_route=\/wp\/v2\/posts\/206175\/revisions\/206176"}],"wp:attachment":[{"href":"http:\/\/namnewsnetwork.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=206175"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"http:\/\/namnewsnetwork.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=206175"},{"taxonomy":"post_tag","embeddable":true,"href":"http:\/\/namnewsnetwork.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=206175"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}